New drug combo shows promise in early cancer trial
Disease control
Completed
This early-phase study tested a new drug called TPST-1495, alone or with pembrolizumab, in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest dose and check…
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:53 UTC